Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06712459
Recruiting Observational

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

NCT06712459 · tracked via the Priya Life Science Italy tracker
Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Observational
Started
2025-10-13
Last updated
2026-01-16

Condition(s) studied

Transformed Splenic Marginal Zone Lymphoma

Study summary

Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations. Exclusion Criteria: * None

Primary outcome measure(s)

  • Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT — 30 months: from the end of samples collection to the end of study analysis
  • Quantification and qualification of lesions acquired at the time of HT. — 30 months: from the end of samples collection to the end of study analysis
  • Prevalence of clonal relationship between SMZL and HT — 30 months: from the end of samples collection to the end of study analysis

Trial sites (7)

FacilityCityRegionStatus
Columbia University New York New York Not Yet Recruiting
Universitz Hospitals Leuven Leuven Belgium Not Yet Recruiting
Hôpital Saint Louis Paris France Recruiting
Fondazione IRCCS Policlinico San Matteo Pavia Italy Recruiting
Hospital Clínic de Barcelona Barcelona Spain Recruiting
Oncology Institute of Southern Switzerland Bellinzona Switzerland Not Yet Recruiting
University Hospitals Dorset Bournemouth United Kingdom Not Yet Recruiting

More International Extranodal Lymphoma Study Group (IELSG) trials in Italy

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma Active, not recruiting
Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach Starting soon
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma Active, not recruiting
Molecular and Cellular Characterization of MALT Lymphoma Starting soon
Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06712459 on ClinicalTrials.gov ↗ ← All trials in Italy